America Great Health (AAGH) 10-K 31 Oct 22 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Document Information Line Items
Entity Registrant Name	America Great Health
Document Type	10-K
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		21,090,218,148
Entity Public Float			$ 0
Amendment Flag	false
Entity Central Index Key	0001098009
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-27873
Entity Incorporation, State or Country Code	WY
Entity Tax Identification Number	98-0178621
Entity Address, Address Line One	1609 W Valley Blvd Unit 338A
Entity Address, City or Town	Alhambra
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91803
City Area Code	(888)
Local Phone Number	988-1333
Security Exchange Name	NONE
Title of 12(b) Security	None
Entity Interactive Data Current	No
Auditor Name	WWC, P.C.
Auditor Location	San Mateo, CA
Auditor Firm ID	1171
No Trading Symbol Flag	true

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Jun. 30, 2021
CURRENT ASSETS
Cash	$ 62,643	$ 396,136
Account receivable, net	918	0
Inventory	116,060	7,848
Other receivable	0	61,136
Advance to supplier	16,964	17,600
TOTAL CURRENT ASSETS	196,585	482,720
Right-of-use asset, net	93,886	126,927
Due from the related parties	8,218	0
Deposits	13,836	700
Property and equipment, net	23,618	12,671
TOTAL ASSETS	336,143	623,018
CURRENT LIABILITIES
Accounts payable and accrued expense	1,437,522	57,209
Income tax payable	102	0
Short term loan	183,932	0
Other payable	334,112	800
Due to related party	573,859	323,750
Deferred income	157,000	0
Lease liability - current	70,895	50,672
TOTAL CURRENT LIABILITIES	2,757,422	432,431
Lease liability – non-current	22,991	76,255
Accrued interest	384,073	0
Long term loan	1,032,138	582,159
Total Non-Current liabilities	1,439,202	658,414
TOTAL LIABILITIES	4,196,624	1,090,845
Commitments and Contingencies	0	0
Redeemable, convertible preferred stock, 10,000,000 shares authorized: Series A voting preferred stock, zero shares issued and outstanding	0	0
Common stock, no par value, unlimited shares authorized; 21,090,218,148 and 21,070,866,399 shares issued and outstanding	0	0
Additional paid-in capital	4,619,991	3,087,869
Accumulated other comprehensive income	160	0
Accumulated deficit	(8,421,849)	(3,555,696)
Total America Great Health stockholder’s deficit	(3,801,698)	(467,827)
Non-controlling interest	(58,783)	0
TOTAL SHAREHOLDERS' DEFICIT	(3,860,481)	(467,827)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 336,143	$ 623,018

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - shares	Jun. 30, 2022	Jun. 30, 2021
Statement of Financial Position [Abstract]
Series A voting preferred stock, shares issued	0	0
Series A voting preferred stock, shares outstanding	0	0
Redeemable, convertible preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	21,090,218,148	21,070,866,399
Common stock, shares outstanding	21,090,218,148	21,070,866,399

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Sales	$ 104,648	$ 195,671
Cost of goods sold	1,588,453	144,318
Gross profit	(1,483,805)	51,353
Selling, general and administrative expenses
Selling expense	86,316	0
General and administrative expense	3,163,977	294,913
	3,250,293	294,913
Loss from operations	(4,734,098)	(243,560)
Other income (expenses)
Interest income	5	0
Interest expense	(190,916)	(20,044)
Loss on equity investment	0	(5,450)
Other income	73	0
	(190,838)	(25,494)
Loss before income taxes	(4,924,936)	(269,054)
NET LOSS	(4,924,936)	(269,054)
Non-controlling interest share of loss	58,783	0
Net loss attributed to the Company	(4,866,153)	(269,054)
Foreign currency transaction	(160)	0
Comprehensive income or loss	$ (4,866,313)	$ (269,054)
BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)	$ 0	$ 0
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED (in Shares)	21,090,049,276	20,438,554,050

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Jun. 30, 2020		$ 3,071,635	$ (3,286,642)			$ (215,007)
Balance (in Shares) at Jun. 30, 2020	20,236,021,836
Issuance of common stock for compensation		2,064				2,064
Issuance of common stock for compensation (in Shares)	206,394,563
Issuance of common stock for debt		135				135
Issuance of common stock for debt (in Shares)	13,450,000
Issuance of common stock for equity trust		700				700
Issuance of common stock for equity trust (in Shares)	70,000,000
Shares issued for M&A		5,450				5,450
Shares issued for M&A (in Shares)	545,000,000
Imputed Interest		7,885				7,885
Net (loss) profit			(269,054)			(269,054)
Balance at Jun. 30, 2021		3,087,869	(3,555,696)			$ (467,827)
Balance (in Shares) at Jun. 30, 2021	21,070,866,399					21,070,866,399
Issuance of common stock for compensation		1,361,133				$ 1,361,133
Issuance of common stock for compensation (in Shares)	11,829,909
Issuance of common stock for debt (in Shares)	6,221,840
Issuance of common stock for equity investment		97,500				97,500
Issuance of common stock for equity investment (in Shares)	1,300,000
Imputed Interest		11,893				11,893
Gain/loss on exchange rate				$ 160		160
Original issue discount on debt		61,596				61,596
Net (loss) profit			(4,866,153)		$ (58,783)	(4,924,936)
Balance at Jun. 30, 2022		$ 4,619,991	$ (8,421,849)	$ 160	$ (58,783)	$ (3,860,481)
Balance (in Shares) at Jun. 30, 2022	21,090,218,148					21,090,218,148

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Statement of Cash Flows [Abstract]
Net loss	$ (4,924,936)	$ (269,054)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	5,905	0
Original issue discount on debt	61,596	0
Stock compensation	1,361,133	2,064
Financing cost	0	135
Loss on equity investment	0	5,450
Imputed interest	11,893	7,885
Changes in operating Assets and Liabilities:
Account receivable	(918)	0
Other receivable	61,771	(58,549)
Other long term asset	(13,138)	0
Other short term asset	0	(17,600)
Inventory	(108,211)	(6,708)
Accounts payable and accrued expense	1,380,314	7,936
Customer advances	157,000	0
Other liabilities	194,318	0
Other payable	333,415	(800)
Net cash used in operating activities from continuing operations	(1,479,858)	(329,241)
Net cash used in operating activities	(1,479,858)	(329,241)
Purchase of property and equipment	(16,851)	(12,671)
Net cash used in investing activities	(16,851)	(12,671)
Cash Flows from Financing Activities
Proceeds from issuance of common stock	97,500	0
Short term loan	183,932	0
Long term loan	639,734	582,159
Advances from related party	250,109	235,331
Repayment to related party	(8,219)	(79,608)
Net cash provided by financing activities	1,163,056	737,882
Net increase in cash	(333,653)	395,970
Cash beginning of period	396,136	166
Effect of foreign currency translation	160	0
Cash end of period	62,643	396,136
Interest paid	0	0
Taxes paid	0	800
Non-cash transactions
Shares issued for equity investment	$ 0	$ 5,450

NATURE OF BUSINESS

NATURE OF BUSINESS	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 NATURE OF BUSINESS History and Organization America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations. On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health. On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California. On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China. On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. This transaction was completed in May 2021 On December 7, 2020, the Company’s wholly-owned Californian subsidiary, America Great Health, entered into a Cooperation Agreement with Brilliant Healthcare Limited (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, raw material procurement, mergers and acquisitions, and consulting services. After the formation of the JV company is completed, the Company shall invest US$4.2 million in the JV Company within the next 24 months for a 60% equity ownership in the JV Company. Brilliant shall transfer its patented technology to the JV Company as its capital contribution, to account for a 40% equity interest in the JV Company. As a condition for AAGH to obtain 60% equity in the JV company and a as the founder of Brilliant, Dr. Aihua Guo agrees to transfer its patent to the JV company as its share of contribution, and AAGH also agrees to pay Dr. Aihua Guo additional compensation, which includes: (i) AAGH transfers 300 million original shares of AAGH to Dr. Aihua Guo at no cost, valuing at $15 million; (ii) AAGH pays Dr. Aihua Guo a one-time cash compensation of $3 million with the following payment schedule: AAGH agrees to pay $500,000 to Dr. Aihua Guo six months from the date of signing of this Agreement, $1.5 million to Dr. Aihua Guo 12 months from the date of signing of this Agreement, and $1 million to Dr. Aihua Guo 24 months from the date of signing of this Agreement. In June 2021, the JV Company was established in Hainan, China as “Sijinsai (Hainan) Biological Tech Ltd.” On July 9, 2021, the Company paid its first investment of $50,000. In July 2021, the Company paid Dr. Aihua Guo $100,000 as prepaid investment. On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology. Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. Currently, several patents are in the application process, and several products are in the process of getting ready for production. On September 3, 2021, the Company entered into an Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to purchase 53 units in 19 real estate properties appraised at $7,626,286.37 for a purchase price of $7,000,000. The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has not been consummated. On November 4, 2021, the Company set up a 100% owned subsidiary Nutrature Health LLC. On November 11, 2021, America Great Health (the “Company”) entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD (“Consultant”). Pursuant to the Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors of the Company, including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and Amylase X. Consultant shall be compensated with a warrant to purchase 500,000 shares of the Company at $0.01 per share within 24 months and a warrant at each of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials and the sale of GOF Biotechnologies Inc. the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages. This Agreement shall be for an initial one-year term and shall renew automatically for successive one-year terms up to a maximum of three (3) years unless terminated by either party pursuant to the Agreement. The 500,000 shares were issued free in April 20, 2022. On November 15, 2021, the Company set up a 100% owned subsidiary GOF Biotechnologies Inc. GOF is 75% majority owned (60,000,000 shares of common stock) by the Company and the remaining 25% of its issued and outstanding shares (20,000,000 shares of common stock) are held by Men Hwei, Tsai. On December 31, 2021, the Company entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment agreement with the Company dated August 31, 2021. The Supplement Agreements provides, inter alia, that Zhigong Lin will be appointed Chief Executive Officer of GOF. The employment agreement and supplement agreement were both terminated by the end of July without the issuance of any GOF shares. On February 4, 2021, the Company set up a 100% owned subsidiary, International Institute of Great Healthcare, Inc. (“IIGH”) under the laws of the State of California. IIGH will bring together doctors and professional-level experts from different countries and regions in the world to the research fields involving bio medicine, clinic medicine, health management, information technology, data analysis, software development, artificial intelligence, industrial planning, financial investment, etc. Going Concern The accompanying consolidated financial statements (“CFS”) were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2022, the Company recorded a net loss of $4,924,936, used cash to fund operating activities of $1,479,858, and on June 30, 2022, had a shareholders’ deficit of $3,860,481. These factors create substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations. Our cash needs for the 12 months ended June 30, 2022 were primarily met by loans and advances from current majority shareholder. As of June 30, 2022, we had a cash balance of $62,643. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Basis of Consolidation The Consolidated Financial Statements includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California (100%), GOF Biotechnologies in California (75%), International Institute of Great Health in California (100%), Nutrature Health LLC in California (100%), Sijinsai in China (60%), and US-China Mega Beauty Health Industry Development Co., LTD, (100%). Intercompany transactions and accounts were eliminated in consolidation. The following table depicts the identity of the Company’s subsidiaries: Name of Subsidiary Place of Attributable America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100 Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates. Foreign Currency Translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. In accordance with ASC 830, “Translation of Financial Statements” the subsidiary’s assets and liabilities booked and recorded at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of foreign subsidiary’s financial statements are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ equity. The Company’s reporting currency is the United States Dollar (“USD”). The Company’s wholly owned subsidiary of Meizhong Health Industry Development Co., Ltd. maintains its books and records in its local currency. The Chinese Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which the subsidiary operates. Below is a table with foreign exchange rates used for translation: June 30, Average Yearly (average rate) Chinese Renminbi (RMB) RMB 6.4554 United States dollar ($) $ 1.00 June 30, Year Ended (Closing rate) Chinese Renminbi (RMB) RMB 6.6993 United States dollar ($) $ 1.00 Cash The Company considers all highly liquid debt instruments purchased with maturity periods of three months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of June 30, 2022 and 2021, the Company’s bank account in the United States had $3,194 and $127,672, respectively, under FDIC insurance of $250,000. Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health related products through wholesale and retailers. The Company has few major wholesale transactions with a new customer in the year ended June 30, 2022. Sales to this customer accounted for approximately 99% of total sales of the year ended June 30, 2022. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company usually does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date and 180 days for a major customer, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time when shipped to customers, for which control is transferred to the customer as goods are delivered to the third party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. Any payment received prior to shipment are recognized as a contract liability under the account deferred revenue. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed by third-party carriers for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the years ended June 30, 2022, the Company has written off $7,956 for inventory in regards to slow moving or obsolete items. Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the year ended June 30, 2022. Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature. Loss Per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2022 and 2021, as there are no potential shares outstanding that would have a dilutive effect. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company did not record a valuation allowance against its deferred tax assets as of June 30, 2022 and 2021. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatory Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatory Redeemable Non-controlling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

OTHER ASSET

OTHER ASSET	12 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	NOTE 3 OTHER ASSET As of June 30, 2022 and 2021, other receivable amounted to $13,836 and $61,136, respectively. Other receivable consists the following: June 30, 2022 June 30, 2021 Rent deposits 13,836 11,136 Loan to a third party - 50,000 Total $ 13,836 $ 61,136

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 4 RELATED PARTY TRANSACTIONS During the year ended June 30, 2022, the Company's current majority shareholder advanced $612,189 to the Company as working capital and the Company repaid $362,081 to the shareholder. As of June 30, 2022 and 2021, the Company owed its current shareholder of $538,669 and $323,750 respectively. The advances are non-interest bearing and are due on demand. Imputed interest amounted $11,893 and $7,885 for the years ended June 30, 2022 and 2021 and was recorded as paid in capital, respectively. Other dues to the related parties are $35,190 as of June 30, 2022.

SHORT TERM LOAN

SHORT TERM LOAN	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Short-Term Debt [Text Block]	NOTE 5 SHORT TERM LOAN As of June 30, 2022, the Company had a short-term loan of $183,932 from unrelated third parties. The two loans totaling $160,000 have six-month short terms. These two loans are due in July and August 2022, interest free, and no collateral. On March 18, 2022, the Company issued 400,000 shares of restricted shares of common stock as bonus shares to the lenders, and another 240,000 shares of restricted shares of common stock were issued in April 12, 2022 as bonus shares as well. The third loan amount is $23,932 which has 8-month short term.

LONG TERM LOAN

LONG TERM LOAN	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Long-Term Debt [Text Block]	NOTE 6 LONG TERM LOAN As of June 30, 2022 and 2021, long term loan amounted to $1,221,892 and $582,159, respectively. The loan has an annual interest rate of 20%. The principal and interest are due in five years. Interest expense incurred for the years ended June 30, 2022 and 2021 amounted to $189,754 and $12,159, respectively. As of June 30, 2022, long term loan consisted of the following: Principal Accrued interest Balance Received long term loan on April 27, 2021 $ 200,000 $ 47,014 $ 247,014 Received long term loan on June 3, 2021 290,000 62,290 352,290 Received long term loan on June 4, 2021 50,000 10,740 60,740 Received long term loan on June 23, 2021 30,000 6,115 36,115 Received long term loan on July 12, 2021 10,000 1,934 11,934 Received long term loan on September 1, 2021 60,000 9,929 69,929 Received long term loan on September 22, 2021 50,000 7,699 57,699 Received long term loan on September 27, 2021 50,000 7,562 57,562 Received long term loan on September 30, 2021 10,000 1,496 11.496 Received long term loan on October 29, 2021 12,138 1,623 13,761 Received long term loan on November 9, 2021 50,000 6,384 56,384 Received long term loan on November 16, 2021 140,000 17,337 157,337 Received long term loan on November 18, 2021 50,000 6,134 56,137 Received long term loan on November 29, 2021 20,000 2,334 22,334 Received long term loan on November 30, 2021 10,000 1,161 11,162 Total $ 1,032,138 $ 189,754 $ 1,221,892 On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. On May 31, 2021, the Company agreed 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed $20,000 on June 3, 2021 and $30,000 on June 23, 2021 and issued 200,000 shares on June 18, 2021 and 240,000 shares on October 28, 2021 with 60,000 shares unissued. On June 18, 2021, the Company issued an aggregate of 2,850,000 shares to 5 unrelated parties as collateral for loans of $270,000. One party with a loan of $100,000 was also awarded 100,000 bonus shares beside the 1,000,000 shares. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. On October 28, 2021, the Company issued 80,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on July 12, 2021. On October 28, 2021, the Company issued 1,540,000 shares to an unrelated party as collateral for loans of $60,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 1, 2021. On October 28, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 22, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in September 27, 2021. On November 22, 2021, the Company issued 100,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 30, 2021. On November 22, 2021, the Company issued 161,840 shares to an unrelated party as collateral for loans of $12,138. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on October 29, 2021. On November 22, 2021, the Company issued 400,000 shares to an unrelated party as collateral for loans of $40,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 16, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 9, 2021. On November 29, 2021, the Company issued 1,000,000 shares to an unrelated party as collateral for a loan of $100,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 16, 2021. On February 2, 2022, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 19, 2021. On February 2, 2022, the Company issued 200,000 shares to an unrelated party as collateral for loan of $20,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 29, 2021. On February 2, 2022, the Company issued 100,000 shares to an unrelated party as collateral for loan of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 30, 2021.

CONVERTIBLE, REDEEMABLE PREFERR

CONVERTIBLE, REDEEMABLE PREFERRED STOCK	12 Months Ended
	Jun. 30, 2022
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 7 CONVERTIBLE, REDEEMABLE PREFERRED STOCK During the year ended June 30, 2016, the Company’s Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred Stock (the “Series A”). The Series A is entitled to a dividend of 4%, when and as declared, and is entitled to a liquidation preference of $1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days. The Series A is also subject to adjustments to the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series A immediately before that change. In August 2016, the Company filed an amendment to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000. There were no preferred shares outstanding as of June 30, 2022 and 2021.

SHAREHOLDERS' DEFICIT

SHAREHOLDERS' DEFICIT	12 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 SHAREHOLDERS DEFICIT At June 30, 2022 and 2021, the Company had 21,090,218,148 and 21,070,866,399 shares of common stock issued and outstanding, respectively. 1) Shares issued for equity investment On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus. The transaction has not been completed by the reporting date. Equity Investment in Purecell Group: On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Because the company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. On March 31, 2022, the Company issued 1,300,000 shares of common stock to an US individual at $0.075 per share. 2) Shares issued for stock compensation On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares was recorded at fair market value of $0.00001 per share.48,220,124 shares were issued at fair market value of $482. On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares was recorded at fair market value of $0.00001 per share. 79,362,534 shares were issued at fair market value of $794. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. 50,000,000 shares were issued at fair market value of $500. On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 6,621,905 shares were issued at fair market value of $66. On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 1,300,000 shares were issued at fair market value of $13. On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 7,140,000 shares were issued at fair market value of $71. On May 18 , 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus. On May 26, 2021, the Company issued 2,000,000 shares of common stock to Dr. Tsai as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 2,000,000 shares were issued at fair market value of $20. On May 26, 2021, the Company issued an aggregate of 450,000 shares of common stock to 3 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 450,000 shares were issued at fair market value of $5. On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 11,300,000 shares were issued at fair market value of $113. On February 2, 2022, the Company issued an aggregate of 10,967,465 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.1195 per share. 10,967,465 shares were issued at fair market value of $1,310,612. On April 1, 2022, the Company issued an aggregate of 75,523 shares of common stock to 1 unrelated party as compensation for services. The issuance of these shares is recorded at fair market value of $0.0685 per share. 75,523 shares were issued at fair market value of $5,173. On April 12, 2022, the Company issued an aggregate of 240,000 shares of common stock to 2 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.06495 per share. 240,000 shares were issued at fair market value of $15,588. On April 20, 2022, the Company issued an aggregate of 500,000 shares of common stock to 1 unrelated party as compensation for services. The issuance of these shares is recorded at fair market value of $0.0595 per share. 500,000 shares were issued at fair market value of $29,750. On May 25, 2022, the Company issued an aggregate of 46,921 shares of common stock to 1 unrelated party as compensation for services. The issuance of these shares is recorded at fair market value of $0.0002 per share. 46,921 shares were issued at fair market value of $9. 3) Shares issued for short term loan as original issue discount On March 18, 2022, the Company issued 400,000 shares of restricted shares of common stock as bonus shares to the lenders with a short term loan amount $100,000, The issuance of these shares is recorded at fair market value of $0.075 per share. 400,000 shares were issued at fair market value of $30,000. On April 12, 2022, the Company issued 240,000 shares of restricted shares of common stock as bonus shares to the lenders with a short term loan amount $60,000, The issuance of these shares is recorded at fair market value of $0.0629 per share. 240,000 shares were issued at fair market value of $15,096. 4) Shares issued for loan as collateral On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. On May 31, 2021, the Company agreed 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed $20,000 on June 3, 2021 and $30,000 on June 23, 2021 and issued 200,000 shares on June 28, 2021 and 240,000 shares on October 28, 2021 with 60,000 shares unissued. On June 18, 2021, the Company issued an aggregate of 2,850,000 shares to 5 unrelated parties as collateral for loans of $270,000. One party with a loan of $100,000 was also awarded 100,000 bonus shares beside the 1,000,000 shares. The Company recorded the 100,000 bonus shares as stock compensation which was included in above part 2 shares issued for stock compensation. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. On October 28, 2021, the Company issued 80,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on July 12, 2021. On October 28, 2021, the Company issued 1,540,000 shares to an unrelated party as collateral for loans of $60,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 1, 2021. On October 28, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 22, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in September 27, 2021. On November 22, 2021, the Company issued 100,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 30, 2021. On November 22, 2021, the Company issued 161,840 shares to an unrelated party as collateral for loans of $12,138. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on October 29, 2021. On November 22, 2021, the Company issued 400,000 shares to an unrelated party as collateral for loans of $40,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 1, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 9, 2021. On November 29, 2021, the Company issued 1,000,000 shares to an unrelated party as collateral for a loan of $100,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 16, 2021. On February 2, 2022, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 19, 2021. On February 2, 2022, the Company issued 200,000 shares to an unrelated party as collateral for loan of $20,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 29, 2021. On February 2, 2022, the Company issued 100,000 shares to an unrelated party as collateral for loan of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 30, 2021. 5) Shares issued in exchange for payable balance On January 28, 2022, the Company signed a company stock and payment exchange agreement with a supplier. The Company offers to pay the supplier the $295,000 for product with 15,000,000 shares of common stock. The 15,000,000 shares of common stock should be transferred to the supplier, or any third party designated by the supplier within 60 days, and no later than March 30, 2022. However, as of September 30, 2022, the Company hasn’t issued any shares of common stock to the supplier for the purchase of products. On January 28, 2022, the Company signed a company stock and payment exchange agreement with a supplier. The Company offers to pay the supplier the $1,100,000 for product with 35,000,000 shares of common stock. The 35,000,000 shares of common stock should be transferred to the supplier, or any third party designated by the supplier within 60 days, and no later than March 30, 2022. However, as of September 30 2022, the Company hasn’t issued any shares of common stock to the supplier for the purchase of products.

EQUITY INVESTMENT

EQUITY INVESTMENT	12 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 9 EQUITY INVESTMENT On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Becausethe company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. The following table summarizes the income statement of Purecell. From date of equity investment to 06/30/2022 Sales $ 687,952 Gross profit 354,513 Net loss (732,815 ) 51% share (366,407 ) The following table provides the summary of balance sheet information for Purecell. As of June 30, 2022 Total assets $ 3,331,381 Net assets 2,413,948 51% ownership 1,231,113 Beginning balance of investment 5,450 Loss on equity investment (5,450 ) Ending balance of investment -

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 10 INCOME TAXES Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards. As of June 30, 2022, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset. Under the Provisional Regulations of The People’s Republic of China Concerning Income Tax on Enterprises promulgated by the PRC, which took effect on January 1, 2008, domestic and foreign companies pay a unified corporate income tax of 25%, except for a 15% corporate income tax rate for qualified high technology and science enterprises. The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2022 and 2021 as follows: Year Ended June 30, 2022 2021 Income tax benefit at federal statutory rate-US 21 % 21 % State tax, net of fed effect-US 7 % 7 % Change in valuation allowance-US (28 )% (28 )% Income tax benefit at federal statutory rate-PRC 25 % 25 % Change in valuation allowance-PRC (25 )% (25 )% - % - % The components of deferred taxes consist of the following at June 30, 2022 and 2021: June 30, 2022 June 30, 2021 Net operating loss carryforwards $ 5,920,531 $ 995,595 Less: valuation allowance (5,920,531 ) (995,595 ) Net deferred tax assets $ - $ - As of June 30, 2022, the Company had federal and California income tax net operating loss carryforwards of $5,920,531. These net operating losses originating in tax years beginning prior to Jan. 1, 2018 will begin to expire 20 years from the date the tax returns are filed. The net operating losses originating in tax years beginning after Jan. 1, 2018 will be carry forwarded indefinitely.

LEASE

LEASE	12 Months Ended
	Jun. 30, 2022
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	NOTE 11 LEASE The Company has entered into an operating leases agreement with GKT, Alhambra, LP. The lease term of the office space is from December 1, 2020 to November 30, 2023. The current monthly rent including monthly management fee is $4,655.64. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements. The Company has entered an operating lease agreement with SoCal Industrial LLC, Irwindale. The lease term of the office space is from June 15, 2021 to May 31, 2023. The current monthly rent including monthly management fee is $1,643.16. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements. The Company had entered a short-term, six-month operating lease for a research lab office building property at $1,161.29 at Cal State Los Angeles University Auxiliary Series, Inc. The lease was terminated by the end of May 2022. Operating lease right-of-use assets and liabilities commencing after December 1, 2020 are recognized at commencement date based on the present value of lease payments over the lease term. For the year ended June 30, 2022, the Company recognized approximately $33,041 in total lease costs. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Year Ended June 30, 2022 Cash paid for operating lease liabilities $ 74,975 Weighted-average remaining lease term 1.75 Weighted-average discount rate 5 % Minimum future lease payments $ 97,219 The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30: 2023 $ 73,941 2024 23,278 2025 - 2026 - Total minimum payments 97,219 Less: imputed interest (3,333 ) Total lease liability 93,886 Less: short-term lease liability (70,895 ) Long-term lease liability $ 22,991

CONCENTRATION

CONCENTRATION	12 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 12 CONCENTRATION Major vendors For the year ended June 30, 2022, one vendor accounted for 10% or more of the Company’s purchases and its outstanding accounts payable balances as at year-end dates, are presented as follows: For the Year Ended As of Supplier Purchases Percentage of Account Supplier A $ 1,550,000 98 % $ 1,395,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 SUBSEQUENT EVENTS On September 15, 2022, the Company paid interest of $3,178 on two short term loans of $50,000 due on July 10, 2022 and $10,000 due on August 1, 2022. The Company then re-entered an agreement of a new short-term loan of $60,000. The loan has an annual interest rate of 18% and the principal and interest are due on February 28, 2023. On September 15, 2022, the Company paid interest of $3,616 on two short term loans, each with $50,000 due on July 26, 2022, and August 1, 2022, and paid $20,000 of principal. The Company then re-entered an agreement of a new short-term, interest free loan of $80,000. The principal is due on February 28, 2023. The Company will issue 1,600,000 shares of the Company stocks to the party as a reward.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).
Consolidation, Policy [Policy Text Block]	Basis of Consolidation The Consolidated Financial Statements includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California (100%), GOF Biotechnologies in California (75%), International Institute of Great Health in California (100%), Nutrature Health LLC in California (100%), Sijinsai in China (60%), and US-China Mega Beauty Health Industry Development Co., LTD, (100%). Intercompany transactions and accounts were eliminated in consolidation. The following table depicts the identity of the Company’s subsidiaries: Name of Subsidiary Place of Attributable America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. In accordance with ASC 830, “Translation of Financial Statements” the subsidiary’s assets and liabilities booked and recorded at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of foreign subsidiary’s financial statements are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ equity. The Company’s reporting currency is the United States Dollar (“USD”). The Company’s wholly owned subsidiary of Meizhong Health Industry Development Co., Ltd. maintains its books and records in its local currency. The Chinese Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which the subsidiary operates. Below is a table with foreign exchange rates used for translation: June 30, Average Yearly (average rate) Chinese Renminbi (RMB) RMB 6.4554 United States dollar ($) $ 1.00 June 30, Year Ended (Closing rate) Chinese Renminbi (RMB) RMB 6.6993 United States dollar ($) $ 1.00
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company considers all highly liquid debt instruments purchased with maturity periods of three months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of June 30, 2022 and 2021, the Company’s bank account in the United States had $3,194 and $127,672, respectively, under FDIC insurance of $250,000.
Revenue [Policy Text Block]	Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health related products through wholesale and retailers. The Company has few major wholesale transactions with a new customer in the year ended June 30, 2022. Sales to this customer accounted for approximately 99% of total sales of the year ended June 30, 2022. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company usually does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date and 180 days for a major customer, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time when shipped to customers, for which control is transferred to the customer as goods are delivered to the third party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. Any payment received prior to shipment are recognized as a contract liability under the account deferred revenue. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed by third-party carriers for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the years ended June 30, 2022, the Company has written off $7,956 for inventory in regards to slow moving or obsolete items.
Equity Method Investments [Policy Text Block]	Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the year ended June 30, 2022.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2022 and 2021, as there are no potential shares outstanding that would have a dilutive effect.
Income Tax, Policy [Policy Text Block]	Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company did not record a valuation allowance against its deferred tax assets as of June 30, 2022 and 2021. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatory Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatory Redeemable Non-controlling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]	The following table depicts the identity of the Company’s subsidiaries: Name of Subsidiary Place of Attributable America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100
Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount [Table Text Block]	Below is a table with foreign exchange rates used for translation: June 30, Average Yearly (average rate) Chinese Renminbi (RMB) RMB 6.4554 United States dollar ($) $ 1.00 June 30, Year Ended (Closing rate) Chinese Renminbi (RMB) RMB 6.6993 United States dollar ($) $ 1.00

OTHER ASSET (Tables)

OTHER ASSET (Tables)	12 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	As of June 30, 2022 and 2021, other receivable amounted to $13,836 and $61,136, respectively. Other receivable consists the following: June 30, 2022 June 30, 2021 Rent deposits 13,836 11,136 Loan to a third party - 50,000 Total $ 13,836 $ 61,136

LONG TERM LOAN (Tables)

LONG TERM LOAN (Tables)	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments [Table Text Block]	As of June 30, 2022, long term loan consisted of the following: Principal Accrued interest Balance Received long term loan on April 27, 2021 $ 200,000 $ 47,014 $ 247,014 Received long term loan on June 3, 2021 290,000 62,290 352,290 Received long term loan on June 4, 2021 50,000 10,740 60,740 Received long term loan on June 23, 2021 30,000 6,115 36,115 Received long term loan on July 12, 2021 10,000 1,934 11,934 Received long term loan on September 1, 2021 60,000 9,929 69,929 Received long term loan on September 22, 2021 50,000 7,699 57,699 Received long term loan on September 27, 2021 50,000 7,562 57,562 Received long term loan on September 30, 2021 10,000 1,496 11.496 Received long term loan on October 29, 2021 12,138 1,623 13,761 Received long term loan on November 9, 2021 50,000 6,384 56,384 Received long term loan on November 16, 2021 140,000 17,337 157,337 Received long term loan on November 18, 2021 50,000 6,134 56,137 Received long term loan on November 29, 2021 20,000 2,334 22,334 Received long term loan on November 30, 2021 10,000 1,161 11,162 Total $ 1,032,138 $ 189,754 $ 1,221,892

EQUITY INVESTMENT (Tables)

EQUITY INVESTMENT (Tables)	12 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments [Table Text Block]	The following table summarizes the income statement of Purecell. From date of equity investment to 06/30/2022 Sales $ 687,952 Gross profit 354,513 Net loss (732,815 ) 51% share (366,407 ) As of June 30, 2022 Total assets $ 3,331,381 Net assets 2,413,948 51% ownership 1,231,113 Beginning balance of investment 5,450 Loss on equity investment (5,450 ) Ending balance of investment -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2022 and 2021 as follows: Year Ended June 30, 2022 2021 Income tax benefit at federal statutory rate-US 21 % 21 % State tax, net of fed effect-US 7 % 7 % Change in valuation allowance-US (28 )% (28 )% Income tax benefit at federal statutory rate-PRC 25 % 25 % Change in valuation allowance-PRC (25 )% (25 )% - % - %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The components of deferred taxes consist of the following at June 30, 2022 and 2021: June 30, 2022 June 30, 2021 Net operating loss carryforwards $ 5,920,531 $ 995,595 Less: valuation allowance (5,920,531 ) (995,595 ) Net deferred tax assets $ - $ -

LEASE (Tables)

LEASE (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Text Block [Abstract]
Lease, Cost [Table Text Block]	Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Year Ended June 30, 2022 Cash paid for operating lease liabilities $ 74,975 Weighted-average remaining lease term 1.75 Weighted-average discount rate 5 % Minimum future lease payments $ 97,219
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30: 2023 $ 73,941 2024 23,278 2025 - 2026 - Total minimum payments 97,219 Less: imputed interest (3,333 ) Total lease liability 93,886 Less: short-term lease liability (70,895 ) Long-term lease liability $ 22,991

CONCENTRATION (Tables)

CONCENTRATION (Tables)	12 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the Year Ended As of Supplier Purchases Percentage of Account Supplier A $ 1,550,000 98 % $ 1,395,000

NATURE OF BUSINESS (Details)

NATURE OF BUSINESS (Details)

1 Months Ended

12 Months Ended

Apr. 20, 2022 shares

Mar. 31, 2022 shares

Nov. 11, 2021 $ / shares shares

Sep. 03, 2021 USD ($)

Jul. 09, 2021 USD ($)

Dec. 07, 2020 USD ($)

Jun. 30, 2020 USD ($) shares

Jan. 19, 2017 USD ($) shares

Jul. 31, 2021 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2021 USD ($)

Nov. 15, 2021 shares

Nov. 04, 2021

Apr. 06, 2021

Feb. 10, 2021

Feb. 04, 2021

NATURE OF BUSINESS (Details) [Line Items]

Stock Issued During Period, Shares, Acquisitions (in Shares) | shares

510,000,000

16,155,746,000

Proceeds from Sales of Business, Affiliate and Productive Assets

$ 100

Payments to Acquire Investments

$ 50,000

Number of Units in Real Estate Property

53

Number of Real Estate Properties

19

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross

$ 7,626,286.37

Payments to Acquire Real Estate

$ 7,000,000

Real Estate, Description of Terms

The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence.

Class of Warrant or Rights, Granted (in Shares) | shares

500,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

Warrants and Rights Outstanding, Term

24 months

Stock Issued During Period, Shares, New Issues (in Shares) | shares

500,000

1,300,000

Investment Owned, Balance, Shares (in Shares) | shares

20,000,000

Net Income (Loss) Attributable to Parent

$ (4,924,936)

$ (269,054)

Net Cash Provided by (Used in) Operating Activities

(1,479,858)

(329,241)

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

$ (215,007)

(3,860,481)

(467,827)

Cash

$ 62,643

$ 396,136

Purecell Group [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

51%

51%

51%

JV Company [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

60%

Brilliant Healthcare Limited [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

40%

Nutrature Health LLC [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

100%

Gof Biotechnologies, Inc. [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

International Institute of Great Health, Inc. (IIGH) [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

Gof Biotechnologies, Inc. [Member]

NATURE OF BUSINESS (Details) [Line Items]

Noncontrolling Interest, Ownership Percentage by Parent

75%

Investment Owned, Balance, Shares (in Shares) | shares

60,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

25%

Corporate Joint Venture [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

$ 4,200,000

Co-venturer [Member]

NATURE OF BUSINESS (Details) [Line Items]

Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)

$ 100,000

Co-venturer [Member] | Common Stock [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

15,000,000

Co-venturer [Member] | Cash Distribution [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

$ 3,000,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Nov. 04, 2021	Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, Uninsured Amount (in Dollars)	$ 3,194		$ 127,672
Cash, FDIC Insured Amount (in Dollars)	250,000
Inventory Valuation Reserves (in Dollars)	$ 7,956
America Great Health California [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%
GOF Biotechnologies in California [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	75%
International Institute of Great Health [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%
Nutrature Health LLC [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%	100%
Sijinsai [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	60%
US-China Mega Beauty Health Industry Development Co., LTD [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	99%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Subsidiaries	12 Months Ended
	Jun. 30, 2022	Nov. 04, 2021
America Great Health California [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%
GOF Biotechnologies in California [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	75%
International Institute of Great Health [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%
Nutrature Health LLC [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%	100%
Sijinsai [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	CHINA
Attributable Equity Interest %	60%
US-China Mega Beauty Health Industry Development Co., LTD [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	CHINA
Attributable Equity Interest %	100%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount	Jun. 30, 2022
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	1
China, Yuan Renminbi | Balance Sheet Items [Member]
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	6.6993
China, Yuan Renminbi | Income Statement Items [Member]
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	6.4554

OTHER ASSET (Details)

OTHER ASSET (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Receivables [Abstract]
Other Receivables	$ 13,836	$ 61,136

OTHER ASSET (Details) - Schedul

OTHER ASSET (Details) - Schedule of Accounts, Notes, Loans and Financing Receivable - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Accounts Notes Loans And Financing Receivable Abstract
Rent deposit	$ 13,836	$ 11,136
Loan to a third party	0	50,000
Total	$ 13,836	$ 61,136

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Proceeds from Related Party Debt	$ 250,109	$ 235,331
Due to Related Parties, Current	573,859	323,750
Imputed Interest	11,893	7,885
Due to Other Related Parties	35,190
Majority Shareholder [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Proceeds from Related Party Debt	612,189
Repayments of Related Party Debt	362,081
Due to Related Parties, Current	538,669	323,750
Imputed Interest	$ 11,893	$ 7,885

SHORT TERM LOAN (Details)

SHORT TERM LOAN (Details) - USD ($)							12 Months Ended
	Apr. 12, 2022	Mar. 18, 2022	Jan. 28, 2022	Oct. 28, 2021	Jun. 28, 2021	Jun. 18, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021
SHORT TERM LOAN (Details) [Line Items]
Short-Term Debt							$ 183,932	$ 183,932	$ 0
Stock Issued During Period, Shares, Other (in Shares)	240,000	400,000	15,000,000	240,000	200,000	1,000,000
Short-Term Debt [Member]
SHORT TERM LOAN (Details) [Line Items]
Short-Term Debt							$ 160,000
Short-Term Debt, Terms							two loans totaling $160,000 have six-month short terms
Short Term Loan #3 [Member]
SHORT TERM LOAN (Details) [Line Items]
Short-Term Debt							$ 23,932
Short-Term Debt, Terms							8-month short term

LONG TERM LOAN (Details)

LONG TERM LOAN (Details)

12 Months Ended

May 25, 2022

Apr. 20, 2022

Apr. 12, 2022 shares

Apr. 01, 2022

Mar. 18, 2022 USD ($) shares

Feb. 02, 2022 USD ($) shares

Jan. 28, 2022 shares

Nov. 29, 2021 USD ($) shares

Nov. 22, 2021 USD ($) shares

Oct. 28, 2021 USD ($) shares

Jun. 28, 2021 shares

Jun. 23, 2021 USD ($)

Jun. 18, 2021 USD ($) shares

Jun. 03, 2021 USD ($)

May 31, 2021 USD ($) shares

May 26, 2021

May 18, 2021

May 05, 2021 USD ($) shares

Apr. 07, 2021

Mar. 10, 2021

Jun. 30, 2022 USD ($) shares

Jun. 30, 2021 USD ($)

LONG TERM LOAN (Details) [Line Items]

Long-Term Debt

$ 1,221,892

$ 582,159

Debt Instrument, Interest Rate, Stated Percentage

20%

Long-Term Debt, Term

5 years

Interest Expense, Debt

$ 189,754

$ 12,159

Stock Issued During Period, Shares, Other (in Shares) | shares

240,000

400,000

15,000,000

240,000

200,000

1,000,000

Debt Instrument, Face Amount

$ 100,000

$ 50,000

$ 100,000

Proceeds from Issuance of Debt

$ 1,032,138

Stock Shares not yet Issued (in Shares) | shares

60,000

Number of Unrelated Parties

1

1

2

1

28

22

3

5

6

12

54

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #1 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Long-Term Debt, Term

5 years

Stock Issued During Period, Shares, Other (in Shares) | shares

10,000,000

Debt Instrument, Face Amount

$ 200,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #2 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Long-Term Debt, Term

5 years

Stock Issued During Period, Shares, Other (in Shares) | shares

240,000

200,000

500,000

Debt Instrument, Face Amount

$ 50,000

Proceeds from Issuance of Debt

$ 30,000

$ 20,000

Stock Shares not yet Issued (in Shares) | shares

60,000

Number of Unrelated Parties

5

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #3 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

20%

Long-Term Debt, Term

5 years

Stock Issued During Period, Shares, Other (in Shares) | shares

2,850,000

Debt Instrument, Face Amount

$ 270,000

Number of Unrelated Parties

5

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 4 [Member]

LONG TERM LOAN (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares) | shares

1,000,000

Debt Instrument, Face Amount

$ 100,000

Loan # 5 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Long-Term Debt, Term

5 years

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #6 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

80,000

Debt Instrument, Face Amount

$ 10,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 7 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

1,540,000

Debt Instrument, Face Amount

$ 60,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 8 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 9 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #10 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

100,000

Debt Instrument, Face Amount

$ 10,000

Debt Instrument, Term

1 year

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #11 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

161,840

Debt Instrument, Face Amount

$ 12,138

Debt Instrument, Term

1 year

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #12 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

400,000

Debt Instrument, Face Amount

$ 40,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 13 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 14 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

1,000,000

Debt Instrument, Face Amount

$ 100,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #15 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #16 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

200,000

Debt Instrument, Face Amount

$ 20,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #17 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

100,000

Debt Instrument, Face Amount

$ 10,000

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Common Stock [Member] | Loan # 4 [Member]

LONG TERM LOAN (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares) | shares

100,000

LONG TERM LOAN (Details) - Sche

LONG TERM LOAN (Details) - Schedule of Long-term Debt Instruments - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Principal	$ 1,032,138
Imputed interest	189,754	$ 12,159
Balance	1,221,892	$ 582,159
Loan Received on April 27, 2021 [Member]
Debt Instrument [Line Items]
Principal	200,000
Imputed interest	47,014
Balance	247,014
Loan Received on June 3, 2021 [Member]
Debt Instrument [Line Items]
Principal	290,000
Imputed interest	62,290
Balance	352,290
Loan received on June 4, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	10,740
Balance	60,740
Loan Received on June 23, 2021 [Member]
Debt Instrument [Line Items]
Principal	30,000
Imputed interest	6,115
Balance	36,115
Loan Received on July 12, 2021 [Member]
Debt Instrument [Line Items]
Principal	10,000
Imputed interest	1,934
Balance	11,934
Loan Received on September 1, 2021 [Member]
Debt Instrument [Line Items]
Principal	60,000
Imputed interest	9,929
Balance	69,929
Loan Received on September 22, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	7,699
Balance	57,699
Loan Received on September 27, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	7,562
Balance	57,562
Loan Received on September 30, 2021 [Member]
Debt Instrument [Line Items]
Principal	10,000
Imputed interest	1,496
Balance	11.496
Loan Received on October 29, 2021 [Member]
Debt Instrument [Line Items]
Principal	12,138
Imputed interest	1,623
Balance	13,761
Loan Received on November 9, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	6,384
Balance	56,384
Loan Received on November 16, 2021 [Member]
Debt Instrument [Line Items]
Principal	140,000
Imputed interest	17,337
Balance	157,337
Loan Received on November 18, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	6,134
Balance	56,137
Loan Received on November 29, 2021 [Member]
Debt Instrument [Line Items]
Principal	20,000
Imputed interest	2,334
Balance	22,334
Loan Received on November 30, 2021 [Member]
Debt Instrument [Line Items]
Principal	10,000
Imputed interest	1,161
Balance	$ 11,162

LONG TERM LOAN (Details) - Sc_2

LONG TERM LOAN (Details) - Schedule of Long-term Debt Instruments (Parentheticals)	12 Months Ended
	Jun. 30, 2022
Loan Received on April 27, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Apr. 27, 2021
Loan Received on June 3, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 03, 2021
Loan received on June 4, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 04, 2021
Loan Received on June 23, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 23, 2021
Loan Received on July 12, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jul. 12, 2021
Loan Received on September 1, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 01, 2021
Loan Received on September 22, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 22, 2021
Loan Received on September 27, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 27, 2021
Loan Received on September 30, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 30, 2021
Loan Received on October 29, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Oct. 29, 2021
Loan Received on November 9, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 09, 2021
Loan Received on November 16, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 16, 2021
Loan Received on November 18, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 18, 2021
Loan Received on November 29, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 29, 2021
Loan Received on November 30, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 30, 2021

CONVERTIBLE, REDEEMABLE PREFE_2

CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) - Series A Preferred Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2016	Aug. 31, 2016
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Shares Authorized	1,000,000	10,000,000
Preferred Stock, Dividend Rate, Percentage	4%
Preferred Stock, Liquidation Preference Per Share	$ 1
Preferred Stock, Redemption Terms	The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”).
Preferred Units, Description	In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days.

SHAREHOLDERS' DEFICIT (Details)

SHAREHOLDERS' DEFICIT (Details)

12 Months Ended

May 25, 2022 USD ($) $ / shares shares

Apr. 20, 2022 USD ($) $ / shares shares

Apr. 12, 2022 USD ($) $ / shares shares

Apr. 01, 2022 USD ($) $ / shares shares

Mar. 31, 2022 $ / shares shares

Mar. 18, 2022 USD ($) $ / shares shares

Feb. 02, 2022 USD ($) $ / shares shares

Jan. 28, 2022 USD ($) shares

Nov. 29, 2021 USD ($) shares

Nov. 22, 2021 USD ($) shares

Oct. 28, 2021 USD ($) shares

Jun. 28, 2021 shares

Jun. 23, 2021 USD ($)

Jun. 18, 2021 USD ($) $ / shares shares

Jun. 03, 2021 USD ($)

May 31, 2021 USD ($) shares

May 26, 2021 USD ($) $ / shares shares

May 18, 2021 USD ($) $ / shares shares

May 11, 2021 USD ($) shares

May 05, 2021 USD ($) $ / shares shares

Apr. 07, 2021 USD ($) $ / shares shares

Apr. 06, 2021 USD ($) $ / shares shares

Mar. 10, 2021 USD ($) $ / shares shares

Feb. 10, 2021 shares

Jan. 22, 2021 $ / shares shares

Jan. 21, 2021 USD ($)

Jun. 30, 2020 shares

Jan. 19, 2017 shares

Jun. 30, 2022 shares

Jun. 30, 2021 USD ($) shares

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Common Stock, Shares, Issued

21,090,218,148

21,070,866,399

Common Stock, Shares, Outstanding

21,090,218,148

21,070,866,399

Stock Issued During Period, Shares, Acquisitions

510,000,000

16,155,746,000

Number of shareholders

28

Shares Issued, Price Per Share (in Dollars per share) | $ / shares

$ 0.0002

$ 0.0595

$ 0.06495

$ 0.0685

$ 0.075

$ 0.075

$ 0.1195

$ 0.00001

$ 0.00001

$ 0.00001

$ 0.00001

$ 0.00001

$ 0.00001

$ 0.00001

$ 0.00001

Stock Issued During Period, Shares, New Issues

500,000

1,300,000

Stock Issued During Period, Shares, Issued for Services

46,921

500,000

240,000

75,523

10,967,465

11,300,000

450,000

7,140,000

1,300,000

6,621,905

50,000,000

79,362,534

48,220,124

Stock Issued During Period, Value, Issued for Services (in Dollars) | $

$ 9

$ 29,750

$ 15,588

$ 5,173

$ 1,310,612

$ 113

$ 5

$ 71

$ 13

$ 66

$ 500

$ 794

$ 482

Number of Unrelated Parties

1

1

2

1

28

22

3

5

6

12

54

Stock Issued During Period, Shares, Other

240,000

400,000

15,000,000

240,000

200,000

1,000,000

Debt Instrument, Face Amount (in Dollars) | $

$ 100,000

$ 50,000

$ 100,000

Stock Issued During Period, Value, Other (in Dollars) | $

$ 30,000

$ 295,000

$ 700

Debt Instrument, Interest Rate, Stated Percentage

20%

Proceeds from Convertible Debt (in Dollars) | $

$ 30,000

$ 20,000

Stock Shares not yet Issued

60,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #1 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

10,000,000

Debt Instrument, Face Amount (in Dollars) | $

$ 200,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #2 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Number of Unrelated Parties

5

Stock Issued During Period, Shares, Other

240,000

200,000

500,000

Debt Instrument, Face Amount (in Dollars) | $

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Stock Shares not yet Issued

60,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #3 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Number of Unrelated Parties

5

Stock Issued During Period, Shares, Other

2,850,000

Debt Instrument, Face Amount (in Dollars) | $

$ 270,000

Debt Instrument, Interest Rate, Stated Percentage

20%

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 5 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

500,000

Debt Instrument, Face Amount (in Dollars) | $

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #6 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

80,000

Debt Instrument, Face Amount (in Dollars) | $

$ 10,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 7 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

1,540,000

Debt Instrument, Face Amount (in Dollars) | $

$ 60,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 8 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

500,000

Debt Instrument, Face Amount (in Dollars) | $

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 9 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

500,000

Debt Instrument, Face Amount (in Dollars) | $

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #10 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

100,000

Debt Instrument, Face Amount (in Dollars) | $

$ 10,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

1 year

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #11 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

161,840

Debt Instrument, Face Amount (in Dollars) | $

$ 12,138

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

1 year

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #12 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

400,000

Debt Instrument, Face Amount (in Dollars) | $

$ 40,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 13 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

500,000

Debt Instrument, Face Amount (in Dollars) | $

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan # 14 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

1,000,000

Debt Instrument, Face Amount (in Dollars) | $

$ 100,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #15 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

500,000

Debt Instrument, Face Amount (in Dollars) | $

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #16 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

200,000

Debt Instrument, Face Amount (in Dollars) | $

$ 20,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Loan #17 [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

100,000

Debt Instrument, Face Amount (in Dollars) | $

$ 10,000

Debt Instrument, Interest Rate, Stated Percentage

20%

Debt Instrument, Term

5 years

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Imediplus Inc. [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Equity Method Investment, Ownership Percentage

5%

Purecell Group [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Equity Method Investment, Ownership Percentage

51%

51%

51%

Purecell Group [Member] | Aussie Produce PTY LTD [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Equity Method Investment, Ownership Percentage

6%

Supplier [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

35,000,000

Stock Issued During Period, Value, Other (in Dollars) | $

$ 1,100,000

Bonus [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Other

100,000

Dr. Tsai [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Shares Issued, Price Per Share (in Dollars per share) | $ / shares

$ 0.00001

Stock Issued During Period, Shares, Issued for Services

2,000,000

8,000,000

Stock Issued During Period, Value, Issued for Services (in Dollars) | $

$ 20

Imediplus Inc. [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Acquisitions

70,000,000

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

2,500,000

Purecell Group [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Shares, Acquisitions

31,212,000

510,000,000

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

510,000,000

510,000,000

510,000,000

Number of shareholders

2

2

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture

50,000,000

Shares Issued, Price Per Share (in Dollars per share) | $ / shares

$ 0.00001

$ 0.00001

Sale of Stock, Number of Shares Issued in Transaction

71,163

Purecell Group [Member] | Aussie Produce PTY LTD [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Shares Issued, Price Per Share (in Dollars per share) | $ / shares

$ 0.00001

Proceeds from Issuance or Sale of Equity (in Dollars) | $

$ 2,340,000

Stock Issued During Period, Shares, New Issues

35,000,000

35,000,000

Sale of Stock, Number of Shares Issued in Transaction

68,372

Loans Payable [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Shares Issued, Price Per Share (in Dollars per share) | $ / shares

$ 0.0629

Stock Issued During Period, Shares, Other

240,000

Debt Instrument, Face Amount (in Dollars) | $

$ 60,000

Loans Payable [Member] | Bonus [Member]

SHAREHOLDERS' DEFICIT (Details) [Line Items]

Stock Issued During Period, Value, Other (in Dollars) | $

$ 15,096

EQUITY INVESTMENT (Details)

EQUITY INVESTMENT (Details)	Apr. 20, 2022 $ / shares shares	Mar. 31, 2022 $ / shares shares	May 26, 2021 $ / shares shares	May 11, 2021 USD ($) shares	Apr. 06, 2021 $ / shares shares	Feb. 10, 2021 shares	Jan. 22, 2021 $ / shares	Jun. 30, 2020 shares	Jan. 19, 2017 shares	May 25, 2022 $ / shares	Apr. 12, 2022 $ / shares	Apr. 01, 2022 $ / shares	Mar. 18, 2022 $ / shares	Feb. 02, 2022 $ / shares	Jun. 18, 2021 $ / shares	May 18, 2021 $ / shares	May 05, 2021 $ / shares	Apr. 07, 2021 $ / shares	Mar. 10, 2021 $ / shares
EQUITY INVESTMENT (Details) [Line Items]
Number of shareholders							28
Shares Issued, Price Per Share (in Dollars per share) | $ / shares	$ 0.0595	$ 0.075	$ 0.00001		$ 0.00001		$ 0.00001			$ 0.0002	$ 0.06495	$ 0.0685	$ 0.075	$ 0.1195	$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001
Stock Issued During Period, Shares, New Issues	500,000	1,300,000
Stock Issued During Period, Shares, Acquisitions								510,000,000	16,155,746,000
Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Equity Method Investment, Ownership Percentage					51%	51%		51%
Aussie Produce PTY LTD [Member] | Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Equity Method Investment, Ownership Percentage				6%
Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares					510,000,000	510,000,000		510,000,000
Number of shareholders					2	2
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture					50,000,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares			0.00001		$ 0.00001
Sale of Stock, Number of Shares Issued in Transaction				71,163
Stock Issued During Period, Shares, Acquisitions				31,212,000				510,000,000
Purecell Group [Member] | Aussie Produce PTY LTD [Member]
EQUITY INVESTMENT (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares			$ 0.00001
Proceeds from Issuance or Sale of Equity (in Dollars) | $				$ 2,340,000
Stock Issued During Period, Shares, New Issues			35,000,000	35,000,000
Sale of Stock, Number of Shares Issued in Transaction				68,372

EQUITY INVESTMENT (Details) - E

EQUITY INVESTMENT (Details) - Equity Method Investments - Purecell Group [Member]	12 Months Ended	40 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)
Schedule of Equity Method Investments [Line Items]
Sales	$ 687,952
Gross profit	354,513
Net loss	(732,815)
51% share	(366,407)
Total assets	3,331,381	$ 3,331,381
Net assets	2,413,948	2,413,948
51% ownership	1,231,113	1,231,113
Beginning balance of investment		5,450
Loss on equity investment		(5,450)
Ending balance of investment	$ 0	$ 0

EQUITY INVESTMENT (Details) -_2

EQUITY INVESTMENT (Details) - Equity Method Investments (Parentheticals)	Jun. 30, 2021
Purecell Group [Member]
Schedule of Equity Method Investments [Line Items]
Share/Ownership	51%

INCOME TAXES (Details)

INCOME TAXES (Details)	12 Months Ended
	Jun. 30, 2022 USD ($)
INCOME TAXES (Details) [Line Items]
Unified Corporate Income Tax, Rate	25%
Corporate Income Tax Rate for Qualified High Technology and Science Enterprises	15%
Foreign Tax Authority [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards (in Dollars)	$ 5,920,531

INCOME TAXES (Details) - Schedu

INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation [Line Items]
State tax, net of fed effect-US	7%	7%
	0%	0%
Domestic Tax Authority [Member]
INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation [Line Items]
Income tax benefit at federal statutory rate	21%	21%
Change in valuation allowance	(28.00%)	(28.00%)
Foreign Tax Authority [Member]
INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation [Line Items]
Income tax benefit at federal statutory rate	25%	25%
Change in valuation allowance	(25.00%)	(25.00%)

INCOME TAXES (Details) - Sche_2

INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Deferred Tax Assets And Liabilities Abstract
Net operating loss carryforwards	$ 5,920,531	$ 995,595
Less: valuation allowance	(5,920,531)	(995,595)
Net deferred tax assets	$ 0	$ 0

LEASE (Details)

LEASE (Details)	12 Months Ended
	Jun. 30, 2022 USD ($)
LEASE (Details) [Line Items]
Operating Lease, Expense	$ 33,041
GKT, Alhambra, LP [Member] | Minimum [Member]
LEASE (Details) [Line Items]
Operating Lease, Expense	4,655.64
SoCal Industrial LLC [Member] | Minimum [Member]
LEASE (Details) [Line Items]
Operating Lease, Expense	1,643.16
Cal State Los Angeles University Auxiliary Series, Inc. [Member] | Minimum [Member]
LEASE (Details) [Line Items]
Operating Lease, Expense	$ 1,161.29

LEASE (Details) - Lease, Cost

LEASE (Details) - Lease, Cost	12 Months Ended
	Jun. 30, 2022 USD ($)
Lease, Cost [Abstract]
Cash paid for operating lease liabilities	$ 74,975
Weighted-average remaining lease term	1 year 9 months
Weighted-average discount rate	5%
Minimum future lease payments	$ 97,219

LEASE (Details) - Lessee, Opera

LEASE (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Lessee Operating Lease Liability Maturity Abstract
2023	$ 73,941
2024	23,278
2025	0
2026	0
Total	97,219
Less: imputed interest	(3,333)
Total lease liability	93,886
Less: short-term lease liability	(70,895)	$ (50,672)
Long-term lease liability	$ 22,991	$ 76,255

CONCENTRATION (Details) - Sched

CONCENTRATION (Details) - Schedules of Concentration of Risk, by Risk Factor - Cost of Goods and Service Benchmark [Member] - Supplier A [Member] - Supplier Concentration Risk [Member]	12 Months Ended
	Jun. 30, 2022 USD ($)
Concentration Risk [Line Items]
Purchases	$ 1,550,000
Percentage of total Purchases	98%
Account Payable	$ 1,395,000

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]	Sep. 15, 2022 USD ($) shares
SUBSEQUENT EVENTS (Details) [Line Items]
Interest Paid, Excluding Capitalized Interest, Operating Activities	$ 3,616
Number of loan agreements	2
Stock Issued During Period, Shares, Other (in Shares) | shares	1,600,000
Short-Term Debt [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Interest Paid, Excluding Capitalized Interest, Operating Activities	$ 3,178
Number of loan agreements	2
Short-Term Debt [Member] | Loan due July 10, 2022 [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount	$ 50,000
Short-Term Debt [Member] | Loan Due August 1, 2022 [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount	10,000
Short-Term Debt [Member] | Loan Due February 28, 2023 [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount	$ 60,000
Debt Instrument, Interest Rate, Stated Percentage	18%
Loan due on July 26, 2022 [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount	$ 50,000
Loan Due August 1, 2022 [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount	20,000
Loan Due February 28, 2023 [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount	$ 80,000